NCCN 非小细胞肺癌指南解读精选.pptVIP

* * * * Mandatory Slide ADDITIONAL INFORMATION A significantly higher percentage of patients in the bevacizumab group were alive at 12 months (51% vs 44.4%) and 24 months (22% vs 15.4%) The median overall survival was 12.3 months vs 10.3 months for the bevacizumab plus PC group vs PC alone The hazard ratio was 0.80, with a 20% relative reduction in the risk of death; P = .013 REFERENCES Avastin? (bevacizumab) prescribing information. South San Francisco, Calif: Genentech; 2006. KEY POINT: Overall survival was significantly prolonged by the addition of bevacizumab to paclitaxel and carboplatin. * * * * * * * * * * * * Note: Possibly combine this slide and the next (TRIBUTE) slide Talking points Highlight the favourable survival data in never smokers from the TALENT trial. Two phase III trials of first-line chemotherapy ± Tarceva: TALENT and TRIBUTE no survival benefit in overall population, but non-smokers experienced significant survival benefit Tarceva exposure appears to be higher in non-smokers1 * * Talking points Highlight the favourable survival data in never smokers in TRIBUTE no survival benefit in overall population, but non-smokers experienced significant survival benefit Tarceva exposure appears to be higher in non-smokers1 1. Hamilton M, et al. Proc Amer Assoc Cancer Res 2005;46 (Abs. 6165). * * * * * * * * * * * * * * * * * * * In order to give a clear conclusion on the treatment of completely resected patients, a meta-analysis on all the CDDP-based chemotherapies used in adjuvant was conducted, and the results presented this year at ASCO. * * * * The LACE meta-analysis confirms the significant impact of adjuvant chemotherapy on survival. NB: The Big Lung Trial (BLT) is a study from Great Britain examining the role of cisplatin-based chemotherapy in a variety of treatment settings in patients with NSCLC. Among these, patients with completely resected stage I-III NSCLC were randomly assigned to three cycles of pre- (4%) or postoperative (96%)